Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries.
about
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionChallenges and opportunities for the implementation of virological testing in resource-limited settingsThe impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.Task-sharing of HIV care and ART initiation: evaluation of a mixed-care non-physician provider model for ART delivery in rural Malawi.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa.Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilitiesFactors influencing adherence to antiretroviral treatment in Asian developing countries: a systematic review.How HIV treatment could result in effective preventionFactors associated with prenatal folic acid and iron supplementation among 21,889 pregnant women in Northern Tanzania: a cross-sectional hospital-based studyLong-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early MortalityPharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Health-care worker engagement in HIV-related quality improvement in Dar es Salaam, Tanzania.Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational databaseMorbidity and mortality among infants born to HIV-infected women in South Africa: implications for child health in resource-limited settings.Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERENon-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settingsBrief Report: Virologic Monitoring Can Be a Cost-Effective Strategy to Diagnose Treatment Failure on First-Line ART.Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message remindersMacrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsLoss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study[Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.Developments in virus-like particle-based vaccines for HIV.Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda.Antiretroviral Adherence Perspectives of Pregnant and Postpartum Women in Guyana.Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy.Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau.Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriageFour years of experience with antiretroviral therapy in adult patients in Karachi, Sindh, Pakistan.Creation of a long-acting nanoformulated dolutegravir.Provision of antiretroviral therapy for children in Nelson Mandela Bay: Health care professionals' challenges.Development of peptide inhibitors of HIV transmission.Prevalence of oral mucosal lesions in adults undergoing highly active antiretroviral therapy in Hong KongBaseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia
P2860
Q24235500-C4E4C421-F1BA-4812-9747-68186A027082Q27026923-6D4DB956-CD23-472E-A7AA-FCD280ADA29FQ31026449-FA68F116-E3FB-4A3D-9827-EDFC26379961Q31140114-5DA7425D-F105-4B38-9C19-4A6122A361F1Q33625213-F78A8136-42E8-4130-8376-9C930A171D96Q33770158-CC1EF20D-0C62-4574-8598-DB632FC580CBQ33875948-5A724EF3-EEE4-4B4E-AD34-ECE6F891DD61Q34038616-463EA46F-293C-46B9-B0B5-D8B67A70095BQ34090397-505F2FD6-4951-4D11-B9B8-20EA22F0E3A1Q34317283-87DCB9FB-1752-4B08-A9F5-3BF393C5BE67Q34731031-E1036876-2F27-4784-A6FE-C3A3920025F0Q34745586-6E3484DF-B58D-4901-8FB0-4CFC9B453440Q34975030-48EF4000-57A1-490B-8F33-F3B262F62694Q34977431-6310E994-F494-4879-A92A-7C9BC66EB644Q35022515-4A6B7448-9134-4A09-A78D-E921A8EDDFF9Q35085621-D9C98D91-E6B1-4754-B222-319B042570E5Q35809718-E3FED1CC-E3A2-4C4F-92D9-73DA1603560FQ35842386-69567087-B8E2-4F57-8765-69820C340E02Q35902391-775A9BF0-B32F-439D-8EE6-CCE2F0CE2410Q36238042-C28F6D27-8519-4B28-A0E0-ADCEDC4FEE18Q36619830-3E258146-5582-4EBD-A759-88AD12144AF9Q37032515-E57F2F6C-C107-4541-AFF7-1DBC6847DD23Q37188867-18B1B595-6AB1-4E43-A5C3-2068D44C05FDQ37256464-2016B7C9-5505-42C7-ABAB-86311CF77F60Q37481106-06EAA9EF-9E7B-46F6-B133-1CF1A3849E37Q37578941-D6D7C346-F9BE-4441-9AC8-4A842A817414Q37955946-7F6107B7-DC80-4B68-A17E-3752761A3B52Q38081965-22DF5C64-A036-424B-B5D4-5C7E98F3C6C7Q38870300-396A5785-ABD7-4AC6-8DAA-4489A60F95B4Q38889090-10DEACF5-45BC-4E18-A7BB-FD2C37408A7DQ40109869-94A36203-D573-482E-AE54-91F3C4DED0A7Q40506176-5277201C-5A25-44F4-988F-2F148BDF4CEAQ42116659-CF6941D0-6A48-48D2-BEB0-453B2031D104Q42247975-3DA0399C-1A75-4D99-AC99-5C8231E8F3E2Q50051618-C564B1EF-741F-4311-8E18-12DBC5149A2FQ54204639-7A3C5467-96BB-4644-A996-242A5E97ADE8Q55317261-C04584C5-7211-4350-ACBC-4852FB58D1B7Q56836280-72B9C640-048B-4738-94D7-445FCA5796B2Q57001782-3E5A6859-8BA2-4EC2-9552-93F2B91BD4D8
P2860
Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Successes, challenges, and lim ...... e and middle-income countries.
@en
Successes, challenges, and lim ...... e and middle-income countries.
@nl
type
label
Successes, challenges, and lim ...... e and middle-income countries.
@en
Successes, challenges, and lim ...... e and middle-income countries.
@nl
prefLabel
Successes, challenges, and lim ...... e and middle-income countries.
@en
Successes, challenges, and lim ...... e and middle-income countries.
@nl
P1476
Successes, challenges, and lim ...... e and middle-income countries.
@en
P2093
John A Bartlett
John F Shao
P304
P356
10.1016/S1473-3099(09)70227-0
P577
2009-10-01T00:00:00Z